Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revive Therapeutics Ltd (OP: RVVTF ) 0.0068 UNCHANGED Streaming Delayed Price Updated: 3:57 PM EST, Nov 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Revive Therapeutics Ltd < Previous 1 2 3 4 5 6 7 8 9 10 Next > Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More April 05, 2023 Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin... Via Benzinga MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update April 03, 2023 Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to... Via Benzinga Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech April 03, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Meth Use Disorder Tackled With Psilocybin: Clinical Trial Begins Patient Enrollment March 28, 2023 Life sciences company Revive Therapeutics Ltd. Via Benzinga Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder March 28, 2023 First subject enrolled and initial top-line results expected in Q3-2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 March 20, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 March 08, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More February 13, 2023 Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More Via Benzinga MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations February 06, 2023 Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve Via Benzinga Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development February 06, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch February 03, 2023 Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items. Via Benzinga Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch February 03, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 January 19, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More January 17, 2023 Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January. Via Benzinga Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 January 12, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders January 12, 2023 Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.< Via Benzinga Revive Therapeutics Ltd. Closes $4.3 Million Offering January 12, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants January 09, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 January 05, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 December 22, 2022 From Revive Therapeutics Ltd. Via GlobeNewswire Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More December 19, 2022 Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Via Benzinga Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials December 16, 2022 Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). Via Benzinga Revive Therapeutics Ltd. Expands Life Offering to Quebec December 15, 2022 From Revive Therapeutics Ltd. Via GlobeNewswire Revive Therapeutics To Raise Up To $5M Via Private Placement December 01, 2022 REVIVE THERAPEUTICS LTD. (OTCQB: RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;. Via Benzinga Revive Therapeutics Ltd. Announces Offering of Up to $5 Million November 30, 2022 From Revive Therapeutics Ltd. Via GlobeNewswire Psychedelic Stock Gainers And Losers From November 30, 2022 November 30, 2022 Via Benzinga Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today November 29, 2022 Via Benzinga Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today November 28, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 25, 2022 November 25, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 24, 2022 November 24, 2022 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
